Yearly Archives: 2018

sphingotec raises €20 million from HBM and Wellington Partners

Diagnostics company SphingoTec GmbH successfully closed €20 million growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners Proceeds will be used to launch the NEXUS IB 10 point-of-care (POC) platform and the novel acute biomarker blood tests sphingotest® penKid® and sphingotest® bio-ADM® Ability to…
Read more

sphingotec is adding an advanced POC testing platform to portfolio

sphingotec is adding an advanced POC testing platform to portfolio SphingoTec GmbH will offer its next-generation sepsis, heart failure and acute kidney injury biomarkers penKid® and bio-ADM® on NEXUS IB 10 point-of-care (POC) testing platform, originally developed by Nexus Dx   penKid® and bio-ADM® are first-in-class biomarkers to diagnose and monitor real-time kidney function and…
Read more

Top